Heterogeneity in major depression and its melancholic and atypical specifiers: a secondary analysis of STAR*D

Lorenzo Lorenzo-Luaces1, John F Buss2, Eiko I Fried3

  • 1Department of Psychological and Brain Sciences, Indiana University, Bloomington, 47405, IN, USA. lolorenz@iu.edu.

BMC Psychiatry
|September 17, 2021
PubMed
Abstract

Insights

The melancholic and atypical specifiers for major depressive episode (MDE) do not reduce symptom heterogeneity. These specifiers may actually increase symptom diversity in depression diagnoses.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Mental Health Research

Background:

  • Major Depressive Episode (MDE) specifiers aim to reduce diagnostic heterogeneity.
  • Previous research suggests the melancholic specifier might increase symptom variability.
  • The impact of melancholic and atypical specifiers on symptom homogeneity in MDE requires further investigation.

Purpose of the Study:

  • To investigate whether melancholic and atypical specifiers reduce symptom heterogeneity in Major Depressive Episode (MDE).
  • To analyze symptom profiles within melancholic, atypical, and general MDE groups.
  • To quantify observed heterogeneity using unique symptom combinations.

Main Methods:

  • Utilized baseline data from 3,717 patients in the Sequenced Alternatives to Relieve Depression (STAR*D) trial.
  • Analyzed a subsample meeting MDE criteria (N=2,496) using the Inventory of Depression Symptoms (IDS).
  • Differentiated patients into melancholic, atypical, and non-specifier groups, quantifying symptom profile heterogeneity.

Main Results:

  • Observed heterogeneity was greater within melancholic and atypical subgroups compared to the general MDE sample.
  • No statistically significant differences in symptom profiles were found between melancholic and non-melancholic groups.
  • Differences between atypical and non-atypical groups were smaller than expected by chance, indicating no reduction in heterogeneity.

Conclusions:

  • Melancholic and atypical specifiers do not create more symptomatically homogeneous groups.
  • These specifiers may introduce additional heterogeneity to the MDE diagnosis.
  • Current evidence does not support the use of these specifiers for reducing symptom presentation variability.

Related Concept Videos

Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
183
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
247
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
435
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
442
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.7K
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
309